Palliation in pancreas cancer;Possibilita di palliazione nel carcinoma pancreatico

Tumori

Volumn 85, Issue 1 SUPPL. 1, 1999, Pages

  Di Costanzo, Francesco ^a   Sdrobolini, Andrea ^a   Gasperoni, Sandra ^a  

^a S MARIA HOSPITAL   (Italy)

Author keywords

Advanced pancreatic carcinoma; Chemotherapy

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; FOLINIC ACID; SPARFOSIC ACID; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; ITALY; MAJOR CLINICAL STUDY; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; TREATMENT INDICATION; TREATMENT PLANNING; CONTROLLED CLINICAL TRIAL; METHODOLOGY; PALLIATIVE THERAPY; PANCREAS TUMOR; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0032619298     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Abruzzese J.L., Evans D., Markowitz A., Patt Y., Pazdur R.: Docetaxel: a potentially active agent for patients with pancreatic adenocarcinomas. Proc. Am. Soc. Clin. Oncol., 14: 221, 1995.
2. Andersen J.R., Friis-Moller A., Hancke S., Roder O., Steen J., Baden H.: A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic cancer. Scand. J. Gastroenterol., 16: 973-975, 1981.
3. Andren-Sanderg A., Homberg J.T., Ihse I.: Treatment of unresectable pancreatic carcinoma with 5-fluorouracil, vincristine, and Ccnu. Scand. J. Gastroenterol., 18: 609-612, 1983.
4. Ardalan B., Sridhar K.S., Benedetto P., Richman S., Waldman S., Morrel L., Feun L., Savaraj N., Fodor M., Livingstone A.: A phase I, II study of high dose 5-fluorouracil and high dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Cancer, 68: 1242-1246, 1991.
5. Borner M.M., Maurer C.A., Friess H., Ludwig C.U., Buchler M.W., Fey M.F.: Gemcitabine (GEM) and continuous infusion fluorouracil (CIF): a phase II study in advanced pancreatic cancer (APC). Ann. Oncol., 9 (Suppl. 4): 241P, 1998.
6. Bukowski R.M., Balcerzak S.P., O'Bryan R.M., Bonner J.D., Chen T.T.: Randomized trial of 5-FU and mitomicin-C with or without streptozotocin for advanced pancreatic cancer. Cancer, 52: 1577-1582, 1983.
7. Buosi R., Alabisio O., Stella A., Dogliotti L., Durando R., La Grotta G., Sidoti V.: A phase I study of gemcitabine and continuous infusion of 5-FU in patients with metastatic pancreatic cancer. Tumori, 84 (Suppl. 1 to No. 5): 211, 1998.
8. rd, Moore M.J., Andersen J., Green M.R., Rothemberg M.L., Modiano M.R., Crippa M.C., Portenoy R.K., Storiolo A.M., Tarassoff P., Nelson R., Dorr F.A.: Improvement in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15: 2403-2413, 1997.
9. Cantore M., et al.: Intra-arterial chemotherapy for advanced carcinoma of the pancreas. Proc. ASCO, 15: 455, 1996.
10. Carter S.K., Comis R.L.: The integration of chemotherapy into a combined modality approch for cancer treatment of pancreatic adenocarcinoma. Cancer Treat. Rev., 2: 193-214, 1975.
11. Cascinu S., Fedeli A., Luzi Fedeli S., Catalano G.: 5-fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: a pilot study. Ann. Oncol., 4: 83-84, 1993.
12. Cascinu S., Frontini L., Labianca R., Silva R., Brown T.D., Flombaum C.D., Trochanowski B., Tarassofi P.G.: Gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a GISCAD phase II study. Proc. ECCO 33 (Suppl. 8): S280 (A1268), 1997.
13. Casper E.S., Green M.R., Kelsen D.P., et al.: Phase II study of gemcitabine (2'2'-difluorodeoxycitidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs, 12: 29-34, 1994.
14. Crinò L., Mosconi A.M., Calandrei C., Corgna E., Darwish S., Tonato M.: Gemcitabine in advanced pancreatic cancer: a phase II trial. Proc. ECCO 33 (Suppl. 8): S280 (A1266), 1997.
15. Crown J., Casper E.S., Botet J., Murray P., Kelsen D.P.: Lack of efficacy of high dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J. Clin. Oncol., 9: 1682-1686, 1991.
16. Cullinam S.A., Moertel C.G., Fleming T.R. Rubin J.R., Krook J.E., Everson L.K., Windschitl H.E., Twito D.I., Maraschke R.F., Foley J.F., Pfeifle Del M., Barlow J.F.: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin and mitomycin. JAMA, 253: 2061-2067, 1985.
17. Cullinam S.A., Moertel C.G., Wieand H.S., Schutt A.J., Krook J.E., Foley J.F., Norris B.D., Kardinal C.G., Tschetter I.K., Barlow J.F.: A phase III trial on the therapy of advanced pancreatic carcinoma. Cancer, 65: 2207-2212, 1990.
18. De Caprio J.A., Mayer R.J., Gonin R., Arbuck S.G.: Fluorouracil and high dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J. Clin. Oncol., 9: 2128-2133, 1991.
19. Di Costanzo F., Tagliaventi M., Carlini P., Zironi S., Mazzocchi B., Bella M., Donati D., Acito L., Maggian P., Angiona S.: High dose folinic acid and fluorouracil with or without ifosfamide is an active combination in advanced pancreatic cancer. Am. J. Clin. Oncol., 19: 307-310, 1996.
20. Dougherty J., Kelsen D., Kemeny N. Magill G., Botet I.: Phase I-II study of cisplatin, high dose ARA-C and caffeine in advanced adenocarcinoma of the pancreas. Proc. ASCO, 7: 98, 1988.
21. Frey C., Twomey P., Keehn R., Elliot D., Higgins G.: Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group. Cancer, 47: 27-31, 1981.
22. The Gastrointestinal Tumor Study Group: Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin-C and two regimens of streptozotocin plus mitomycin-C plus fluorouracil. J. Clin. Oncol., 4: 1794-1798, 1986.
23. Glimelius B., Hoffmann K., Sjoden P.-O., Jacobsson G., Sellström H., Ernander L.K., Linne T., Svensson C.: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol., 7: 593-600, 1996.
24. Heinemann V., Wilke H., Possinger K., Mergenthaler K., Clemens M., Konig H.J., Illiger H.J., Lackhoff A., Blatter J., Schallhorn A., Fink U.: Activity and tolerability of gemcitabine plus cisplatin in advanced metastatic pancreatic carcinoma. Proc. ECCO 33 (Suppl. 8): S274 (A1240), 1997.
25. Hidalgo M., Paz-Arez L., Hitt R., Alonso S., Diaz-Puente M., Catellanos D., Cortès-Funes H.: Phase I-II study of gemcitabine combined with continous infusion 5-FU as first line chemotherapy in locally advanced and metastatic pancreatic cancer. Proc. ASCO, 16: 290 (A 1030), 1997.
26. Lionetto R., Pugliese V., Bruzzi P., Rosso R.: No standard treatment is available for advanced pancreatic cancer. Eur. J. Cancer, 31A: 882-887, 1995.
27. Loh K., Stuart K., Cohn A, White C., Hines J., Miller W., Green M.R., Chew T., Johnston A., Clendeninn N.: A phase trial of thymidaq (AG 337) in patients with adenocarcinoma of the pancreas. Proc. Am. Soc. Clin. Oncol. 16: 265a (Abs 938), 1997.
28. Mallinson C.N., Rake M.O., Cocking J.B., Fox C.A., Cwynarski M.T., Diffey B.L., Jackson G.A., Hanley J., Wass V.J.: Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomized, multicentre trial. BMJ, 281: 1589-1591, 1980.
29. Morrell L.M., Bach A., Richman S.P., Goodman P., Fleming T.R., Mac Donald J.S.: A phase II multi-institutional trial of low dose N-(phosphonacetyl)-L-aspartate and high dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. Cancer, 67: 363-366, 1991.
30. Mortel C.G., Rubin J., O'Connell M.J., Schutt A.J., Weiand H.S.: A phase II study of combined 5-fluorouracil, doxorubicin and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J. Clin. Oncol., 7: 1053, 1986.
31. Nicolson M., Webb A., Cunningham D., Norman A., O'Brien M., Hill A., Hickish T.: Cisplatin and protracted venous infusion 5-fluorouracil (CF) good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann. Oncol., 6: 801-804, 1995.
32. Oster M.W., Gray R., Panasci L., Perry M.C.: Chemotherapy for advanced pancreatic cancer. Cancer, 57: 29-33, 1986.
33. Palmer K., Kerr M., Knowles G., Cull A., Carter D., Leonard R.: Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br. J. Surg., 81: 882-885, 1994.
34. 2A in previously untreated patients with pancreatic adenocarcinoma. Cancer, 70: 2073-2076, 1992.
35. Pazdur R., Meropol N.J., Casper E.S. Douglass H.O. Jr, Vincent M., Abbruzzese J.L.: Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Invest. New Drugs, 13: 355-358, 1996.
36. Polyzos A., Tsavaris N., Kosmas C., Arnaoutis T.H., Apostolopoulos P.: Gemcitabine (GEM) plus 5-fluorouracil (5-FU) modulated by leucovorin (LV) for advanced pancreatic cancer. Ann. Oncol., 9 (Suppl. 4): 262, 1998.
37. Rothenberg M.L., Moore M.J., Cripps M.C., Andersen J.S., Portenoy R.K., Burris H.A., Green M.R., Tarassof P.G., Brown T.D., Casoer E.S., Storniolo A.M., Von Hoff D.D.: A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann. Oncol., 7: 347-353, 1996.
38. Rougier Ph., De Forni M., Adenis A, Ducreux M., Djazouli K., Adams D., Boonneterre J., Clouet P., Blanc C., Bayssas M., Armand J.P.: Phase II study of taxotere (RP 56976, docetaxel) in pancreatic adenocarcinoma (PAC). Proc. Am. Soc. Clin. Oncol., 13: 200 (Abs. 587), 1994.
39. Sawabe Y., Yamagishi H., Yamaguchi N., Yamamura Y., Oka T.: In vitro chemosensitivity of human pancreatic cancer cell lines. Int. J. Pancreatol., 20: 185-190, 1996.
40. Scheithauer W., Pfeffel F., Kornek G., Marczell A., Wiltschke C., Funovics J.: A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. Cancer, 70: 1864-1866, 1992.
41. Schilder R.J., Paul A.R., Walczak J., DiFino S.M., Flynn P.J., Banneerjee T.K., Beim W.J., Comis R.L., Ozols R.F., O'Dwyer P.J.: Phase II trial of PALA/5-FU in pancreatic cancer. Proc. Am. Soc. Clin. Oncol., 9: 109 (Abs 422), 1990.
42. Smith P.P., Rustgi V.K., Schertz G., Woolley P.V., Schein P.S.: Phase II study of 5-FU, doxorubicin and mitomycin (FAM) and chlorozotocin in advanced measurable pancreatic cancer. Cancer Treat. Rep., 66: 2095-2096, 1982.
43. Soldan M., Netter K.J., Maser E.: Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells. Biochem. Pharmacol., 51: 117-123, 1996.
44. Sugarman S.M., Pazdur R., Daughterty K., Evans D., Winn R., Dubovsky D., Goodwin J.W., Abruzzese J.L.: A phase II trial of topotecan (TPT) for the treatment of unresectable pancreatic cancer. Proc. Am. Soc. Clin. Oncol., 13: 224 (Abs.), 1994.
45. Tempero M.A., Sivinski C., Steplewski Z., Harvey E., Klassen L., Kay H.D.: Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects. J. Clin. Oncol., 8: 2019-2026, 1990.
46. Wagener D.J.T., Verdonk H., Dirix L.Y. Catimel G., Siegenthaler P., Buitenhuis M., Mathieu-Bouè A., Verweij J.: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann. Oncol., 6: 129-132, 1994.
47. Watanabe N., Tsuji N., Tsuji Y., et al.: Endogenous tumor necrosis factor inhibits the cytotoxicity of exogenous tumor necrosis factor and adriamycin in pancreatic carcinoma cells. Pancreas, 13: 1639-1645, 1981.
48. Whitehead R., Jacobson J., Brown T., Taylor S., Weiss G., Macdonald J.: Phase II trial of paclitaxel and granulocyte colony stimulating factor in patients with pancreatic carcinoma: a Southwest Group Study. J. Clin. Oncol., 15: 2414-2419, 1997.
49. Wiggans R.G., Woolley P.V., Macdonald J.S., Smythe T., Ueno W., Schein P.S.: Phase II trial of streptozotocin, mitomycin-C, and 5-fluorouracil (SMF) in the treatment of pancreatic cancer. Cancer, 41: 387-391, 1978.